Pfizer’s (PFE) Buy Rating Reiterated at Guggenheim

Pfizer (NYSE:PFE)‘s stock had its “buy” rating restated by equities researchers at Guggenheim in a research report issued on Tuesday,Benzinga reports.

Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Up 0.8 %

Shares of PFE stock traded up $0.22 on Tuesday, hitting $26.27. The stock had a trading volume of 4,691,042 shares, compared to its average volume of 35,695,413. The business has a 50 day moving average of $26.22 and a 200 day moving average of $27.10. The stock has a market cap of $148.85 billion, a price-to-earnings ratio of 18.63, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. As a group, analysts expect that Pfizer will post 2.95 EPS for the current year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the fourth quarter worth approximately $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.